Jared Keller
@Kynam Capital Management, Lp
Latest period2024 - Q3ReportedManaged Assets$1.304BTotal holdings25
Assets growth rate0.63%Assets growth rate (2-Q avg)18.16%Continuous growth in asset value4 quarters
Portfolio positions
This chart displays the top 10 holdings in Kynam Capital Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 25 positions.
Assets under management
The assets under management (AUM) of Kynam Capital Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.304B in assets, with a quarterly growth rate of 0.63% and a 2-quarter average growth rate of 18.16%. The portfolio is managed by Jared Keller, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
WVEWave Life Sciences Ltd
| 3.08% | $40.176M 4.899M shares@ $8.2 avg price | Increased 23.25% |
BEAMBeam Therapeutics Inc
| 2.45% | $31.901M 1.302M shares@ $24.51 avg price | New Position |
TSVT2seventy Bio Inc
| 2.16% | $28.102M 5.954M shares@ $4.72 avg price | |
LQDALiquidia Corporation
| 1.74% | $22.663M 2.266M shares@ $10.0 avg price | Increased 147.27% |
PTGXProtagonist Therapeutics Inc
| 1.58% | $20.537M 456,369 shares@ $45.0 avg price | Decreased -42.95% |
TVTXTravere Therapeutics Inc
| 1.48% | $19.187M 1.372M shares@ $14.0 avg price | Decreased -32.15% |
IRWDIronwood Pharmaceuticals Inc
| 1.17% | $15.185M 3.686M shares@ $4.13 avg price | Increased 124.48% |
VRTXVertex Pharmaceuticals Inc
| 1.07% | $13.952M↓ Put 30,000 shares@ $465.08 avg price | Decreased -90.9% |
ENGNEngene Holdings Inc
| 0.88% | $11.459M 1.736M shares@ $6.6 avg price | New Position |
TYRATyra Biosciences Inc
| 0.85% | $11.001M 467,947 shares@ $23.52 avg price | Decreased -17.42% |